These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12878575)

  • 21. Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?
    Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
    Curr Vasc Pharmacol; 2010 Jan; 8(1):1-4. PubMed ID: 20394107
    [No Abstract]   [Full Text] [Related]  

  • 22. Risk of hypoglycemia with antihypertensive medication.
    Gambassi G; Carbonin P; Bernabei R
    JAMA; 1997 Nov; 278(19):1569-70; author reply 1570-1. PubMed ID: 9370497
    [No Abstract]   [Full Text] [Related]  

  • 23. [The real problem in diabetes (trial of gliclazide, an original molecule with metabolic and vascular properties)].
    Masbernard A; Portal A
    Therapeutique; 1972 Nov; 48(9):569-73. PubMed ID: 4650526
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomized clinical trials: prescriptions to be applied with caution!
    Alderman MH
    Am J Hypertens; 2008 May; 21(5):483-4. PubMed ID: 18437132
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of insulin sensitizers in diabetes.
    Jawa A; Fonseca V
    Curr Opin Investig Drugs; 2006 Sep; 7(9):806-14. PubMed ID: 17002258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacotherapeutical features of arterial hypertension in patients with diabetes mellitus].
    Okunevich IV; Khnychenko LK; Sapronov NS
    Klin Med (Mosk); 2007; 85(1):52-7. PubMed ID: 17419357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Cushman WC; Grimm RH; Cutler JA; Evans GW; Capes S; Corson MA; Sadler LS; Alderman MH; Peterson K; Bertoni A; Basile JN;
    Am J Cardiol; 2007 Jun; 99(12A):44i-55i. PubMed ID: 17599425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of drug therapy and risk factors in diabetic hypertensives: a study of the quality of care provided in diabetic clinics in Bahrain.
    Al Khaja KA; P Sequeira R; Damanhori AH
    J Eval Clin Pract; 2005 Apr; 11(2):121-31. PubMed ID: 15813710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ADVANCE: action in diabetes and vascular disease.
    Patel A; Chalmers J; Poulter N
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Journal of Hypertension. Introduction.
    Chalmers J; Zanchetti A
    J Hypertens Suppl; 2007 Jun; 25(1):S1-2. PubMed ID: 17579312
    [No Abstract]   [Full Text] [Related]  

  • 32. Vascular disease risk markers in diabetes: monitoring & intervention.
    Winters S; Jernigan V
    Nurse Pract; 2000 Jun; 25(6 Pt 1):40, 43-6, 49 passim; quiz 65-7. PubMed ID: 10884996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study.
    Tillin T; Orchard T; Malm A; Fuller J; Chaturvedi N
    J Hypertens; 2011 Jul; 29(7):1457-62. PubMed ID: 21602709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of hypertension in patients with type 2 diabetes mellitus].
    Hess K
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2489-92. PubMed ID: 23114910
    [No Abstract]   [Full Text] [Related]  

  • 35. [Normalization of blood pressure and lipids in patients with diabetes].
    Clemens A; Gallwitz B
    Med Klin (Munich); 2003 Jul; 98(7):368-76. PubMed ID: 12937902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycemic control in the prevention of diabetic complications.
    Ratner RE
    Clin Cornerstone; 2001; 4(2):24-37. PubMed ID: 11838325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    Studney D
    Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
    Gerstein HC; Yusuf S; Holman R; Bosch J; Pogue J;
    Diabetologia; 2004 Sep; 47(9):1519-27. PubMed ID: 15322749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up after tight control of blood pressure in type 2 diabetes.
    Holman RR; Paul SK; Bethel MA; Neil HA; Matthews DR
    N Engl J Med; 2008 Oct; 359(15):1565-76. PubMed ID: 18784091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
    Fabian W; Majkowska L; Stefański A; Moleda P
    Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.